PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
NCT00922428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1389
Last updated 2015-05-04
Summary
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.
Conditions
- Rheumatic Diseases
- Arthralgia
- Myalgias/Myopathy
- Lumbago
Sponsors & Collaborators
-
Pascoe Pharmazeutische Praeparate GmbH
lead INDUSTRY
Principal Investigators
-
Anja Braschoss, MD · Pascoe Pharmazeutische Praeparate GmbH
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-01-31
- Primary Completion
- 2009-05-31
- Completion
- 2009-05-31
More Related Trials
-
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
NCT00982332 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
NCT02473965 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT02965573 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA
-
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT05374590 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Add-on Intravenous Immunoglobulins in Early Myositis
NCT05832034 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
NCT04980495 ·Status: COMPLETED ·Phase: PHASE3
-
Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis
NCT03092154 ·Status: TERMINATED ·Phase: NA
-
A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations
NCT02413580 ·Status: COMPLETED ·Phase: PHASE3
-
Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection
NCT03166761 ·Status: TERMINATED ·Phase: PHASE4
-
Mycophenolate Mofetil in Myasthenia Gravis
NCT00285350 ·Status: COMPLETED ·Phase: PHASE3
-
Deflazacort in Dysferlinopathies
NCT00527228 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
NCT00542997 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
NCT07223632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Intravenous Immunoglobulins in Complex-regional Pain Syndrome
NCT00949065 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565 ·Status: RECRUITING
-
The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.
NCT05947578 ·Status: COMPLETED ·Phase: PHASE1
-
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
NCT01560052 ·Status: COMPLETED ·Phase: NA
-
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
NCT04818671 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
NCT00987116 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
NCT05681715 ·Status: COMPLETED ·Phase: PHASE3